Large drugmakers cheapest against their own PE history

Ranked

17

of 412 large drugmakers we cover

Median

41st pct

Lowest

2nd pct

ANIP

Range

2nd pct to 100th pct

#	Company	PE vs its 10 years	PE	Its 10y median PE	Market cap
1	ANIPANI Pharmaceuticals	2nd pct	15.4×	60.6×	$1.7B
2	NATRNatures Sunshine Products	6th pct	12.0×	20.6×	$213.8M
3	BMYBristol-Myers Squibb	10th pct	13.5×	19.9×	$125.6B
4	JAZZJazz Pharmaceuticals	15th pct	14.6×	20.2×	$13.9B
5	PAHCPhibro Animal Health	20th pct	15.9×	21.5×	$1.6B
6	AMPHAmphastar Pharmaceuticals	25th pct	14.8×	20.6×	$1.1B
7	PBHPrestige Consumer Healthcare	28th pct	13.4×	15.3×	$2.3B
8	LFVNLifevantage	30th pct	14.7×	19.6×	$73.4M
9	LGNDLigand Pharmaceuticals	41st pct	32.3×	37.7×	$6.1B
10	LLYEli Lilly and	52nd pct	42.7×	41.4×	$1.2T
11	AMGNAmgen	79th pct	27.3×	21.1×	$237.5B
12	ABBVAbbVie	88th pct	80.7×	27.9×	$504.8B
13	JNJJohnson & Johnson	90th pct	40.0×	24.3×	$635.8B
14	MRKMerck	93rd pct	116×	24.9×	$358.4B
15	CORTCorcept Therapeutics	94th pct	204×	28.3×	$9.3B
16	PFEPfizer	98th pct	39.5×	15.8×	$171.2B
17	BIIBBiogen	100th pct	44.4×	16.1×	$37B

Not ranked: 325 with no PE (losses over the last year), 15 with under ten years of history. 55 companies whose data behind this number has a caveat are left out until it is checked.

A ranking of numbers, not a recommendation. A low multiple can be a bargain or a business in trouble: open the company to see which.